TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04479280

Intervention type: DEVICE
Intervention: Sonclot Coagulation and platelet function Analyzer SCP1, Sienco, USA
Description: studying coagulation disorders in COVID19 critically ill patients
Study: NCT00879996

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methadone
Description: Oral, 10-60 mg per day, 2-4 times per day, 6 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine/naloxone
Description: Sub-lingual, 4-16 mg per day, divided 2-4 times/day, 6 months
Study: NCT02822560

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: pEVAR
Description: percutaneous femoral access using a suture-mediated closure device

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: open femoral access
Description: cutdown to femoral artery and surgical closure
Study: NCT03564782

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PVSRIPO
Description: The live, attenuated, oral (Sabin), serotype 1 poliovirus vaccine booster will be administered 1 week before PVSRIPO injection. The study drug, PVSRIPO, is the live attenuated, oral (Sabin) serotype 1 poliovirus vaccine containing a heterologous internal ribosomal entry site (IRES) derived from the human rhinovirus type 2 (HRV2). It will be given at a dose of 1x10\^8 TCID50 (tissue culture infectious dose) directly into the breast tumor.
Study: NCT02354963

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: In vitro fragmentation of the ovarian tissue
Description: Unilateral ovarian cortex extraction, in vitro fragmentation and reimplantation.
Study: NCT04257708

Intervention type: DIAGNOSTIC_TEST
Intervention: ultrasound
Description: Transvaginal us to assess the cavity

Intervention type: DIAGNOSTIC_TEST
Intervention: ultrasound
Description: Transvaginal us to assess the cavity
Study: NCT01947660

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Systemic analgesia + Continuous regional anesthesia
Description: Systemic analgesia + Continuous regional anesthesia, peri neural for the 2 to 4 first days post-operative

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Systemic analgesia
Description: Systemic analgesia as usual
Study: NCT01047722

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin ingestion followed by doing a Bleeding Volume Test
Description: Patient drinks a glass of Gatorade containing 325 mg of aspirin, then one hour later a bleeding volume test is performed.
Study: NCT04056117

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Shigella 4V
Description: Non-adjuvanted and adjuvanted Shigella 4V administrated at 4 different doses: very low, low, medium and high.

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: MenACWY
Description: Control vaccine administrated to adults and infants

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MenACWY
Description: Control vaccine administrated to adults and infants

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Rabies
Description: Control vaccine administrated to children
Study: NCT01047722

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Gatorade Placebo followed by Bleeding Volume Test.
Description: Patient drinks a glass of Gatorade, then one hour later a bleeding volume test is performed.
Study: NCT01372605

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Measurement-Based Care collaborative depression management
Description: Depression Care Manager collects metrics on depressive severity and side effects and provides decision support regarding antidepressant initiation and modification to HIV providers who prescribe medications

Intervention type: OTHER
Group type: OTHER
Intervention: Enhanced Usual Care
Study: NCT01097252

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation
Description: radiation with cisplatin 40mg/m2, 6 cycles, every week

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: radiation
Description: radiation with cisplatin 40mg/m2, 6 cycles, every week

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: weekly cisplatin
Description: weekly cisplatin 40mg/m2, 6 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tri-weekly cisplatin
Description: cisplatin 75mg/m2, 3cycles, every 3 weeks
Study: NCT03928145

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chlorthalidone 25 mg
Description: Chlorthalidone 25 mg taken orally in the morning for 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorthalidone 25 mg
Description: Chlorthalidone 25 mg taken orally in the morning for 12 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrochlorothiazide 50 mg
Description: Hydrochlorothiazide 50 mg taken orally in the morning for 12 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrochlorothiazide 50 mg
Description: Hydrochlorothiazide 50 mg taken orally in the morning for 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amiloride 20 mg
Description: Amiloride 20 mg taken orally in the morning for 12 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amiloride 20 mg
Description: Amiloride 20 mg taken orally in the morning for 12 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amiloride 10 mg
Description: Amiloride 10 mg taken orally in the morning for 12 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amiloride 10 mg
Description: Amiloride 10 mg taken orally in the morning for 12 weeks.
Study: NCT04056117

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Diphtheria, Tetanus and Pertussis (DTaP)
Description: Control vaccine administrated to infants

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Control administrated to adults
Study: NCT02183116

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Meloxicam
Study: NCT01720823

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: home polysomnography (GETEMED)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: standard polysomnography (BRAINNET II)
Study: NCT01339598

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial direct current stimulation (Eldith DC Stimulator)
Description: Eldith DC Stimulator (NeuroConn GmbH, Germany)

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial direct current stimulation (Eldith DC Stimulator)
Description: Eldith DC Stimulator (NeuroConn GmbH, Germany)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial direct current stimulation (Eldith DC Stimulator)
Description: Eldith DC Stimulator (NeuroConn GmbH, Germany)
Study: NCT04372160

Intervention type: OTHER
Intervention: Dietary assessment
Description: 24-hr dietary recall

Intervention type: OTHER
Intervention: Dietary assessment
Description: 24-hr dietary recall

Intervention type: OTHER
Intervention: Dietary assessment
Description: 24-hr dietary recall
Study: NCT03705455

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: ISAP SMS
Description: ISAP SMS is a text message for caregivers use that provides immunization schedule and vaccine availability at the nearest immunization clinic.
Study: NCT01167686

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Gardemont Goldtrain Plus (GT+)
Description: Four tablets of 760 mg of GT+ administered three times a day for seven consecutive days and similar placebo tablets given to the control arm
Study: NCT04266288

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Active drug
Study: NCT03196466

Intervention type: BIOLOGICAL
Intervention: phenobarbital
Description: titration

Intervention type: BIOLOGICAL
Intervention: phenytoin
Description: titration

Intervention type: BIOLOGICAL
Intervention: phenytoin
Description: titration

Intervention type: BIOLOGICAL
Intervention: levetiracetam
Description: titration
Study: NCT04266288

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sodium Chloride 0.9%
Description: Placebo
Study: NCT00572338

Intervention type: OTHER
Intervention: No drugs are involved
Description: No treatment or drugs are involved in this research. Participating in this study requires that blood and bone marrow samples be obtained as a part of the diagnostic work-up or follow-up of participant's multiple myeloma. Bone marrow/peripheral blood samples will be collected at the same time for research purposes. Data will be collected including demographic information gathered from your medical record, including gender, date of birth, ethnicity, date of diagnosis, laboratory and pathology results, treatment protocols, dates of relapses, subsequent treatment protocols, and current treatments and medications.
Study: NCT02544802

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adipose-Derived Mesenchymal Stem Cells
Study: NCT00779558

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Heparin sulfate infusion at 10 units/kg/hour
Description: Infusion of heparin to prevent central line thrombosis in infants after cardiac surgery

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo infusion
Description: Infusion of normal saline
Study: NCT00980005

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK investigational vaccine GSK1557482A
Description: One intramuscular injection for primed subjects, two intramuscular injections for unprimed subjects

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Fluzone®
Description: One intramuscular injection for primed subjects, two intramuscular injections for unprimed subjects
Study: NCT02378519

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Web-prog, followed by CBT + PT
Description: This arm of the single system experimental design starts with a baseline phase of 8 weeks where the subjects are introduced into to the interactive web-based self-help program. The baseline-period is followed by the intervention period which consists of a continued use of the interactive web-based self-help program, now with with cognitive behavioral therapy coaching in combination with individually tailored physiotherapy according to the person's needs for 16 weeks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Base, followed by Web + CBT + PT
Description: The intervention consists of a interactive web-based selfadministrated program with cognitive behavioral therapy coaching in combination with tailored physiotherapy according to the person's needs for 16 weeks.
Study: NCT05707611

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Running
Description: The participant perform running on treadmill at moderate intensity exercise 30 minutes/time. Physiological variables, lung function variables, allergic rhinitis symptoms variables, and cytokines level in nasal secretion variables were analyzed during pre-and post-exercise.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cycling
Description: The participant perform cycling on cycle ergometer at moderate intensity exercise 30 minutes/time. Physiological variables, lung function variables, allergic rhinitis symptoms variables, and cytokines level in nasal secretion variables were analyzed during pre-and post-exercise.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Swimming
Description: The participant perform swimming at moderate intensity exercise 30 minutes/time. Physiological variables, lung function variables, allergic rhinitis symptoms variables, and cytokines level in nasal secretion variables were analyzed during pre-and post-exercise.
Study: NCT01973036

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Foley Catheter
Description: The balloon will be inflated with 30 cc of sterile saline. The catheter will be taped to the patient's leg so that traction is maintained. The catheter will be assessed hourly for expulsion by a health care provider by applying gentle traction on the catheter or a vaginal examination if it is unclear by traction. Once the Foley catheter is expelled or 12 hours reached, the induction will be continued with oxytocin per this protocol.
Study: NCT03196466

Intervention type: BIOLOGICAL
Intervention: levetiracetam
Description: titration

Intervention type: BIOLOGICAL
Intervention: lamotrigine
Description: titration
Study: NCT01973036

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: Each arm will receive oxytocin at a rate of 2 milliunits/milliliter. If the fetal status is reassuring, this can be increased by 2 milliunits/milliliter every 30 minutes to achieve an adequate contraction pattern as per the institution's definition to a maximum of 30 milliunits/milliliter. This infusion may be continued until delivery.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin
Description: Each arm will receive oxytocin at a rate of 2 milliunits/milliliter. If the fetal status is reassuring, this can be increased by 2 milliunits/milliliter every 30 minutes to achieve an adequate contraction pattern as per the institution's definition to a maximum of 30 milliunits/milliliter. This infusion may be continued until delivery.
Study: NCT03108729

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eslicarbazepine acetate
Description: Eslicarbazepine acetate tablets, taken once daily for 1 year. The daily maintenance dose will be within the range of 300 mg to 1600 mg ESL, and is determined by body weight, clinical response and tolerability.
Study: NCT04106843

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lutetium Lu 177 Dotatate
Description: Given IV
Study: NCT02082626

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eribulin mesylate
Study: NCT03357367

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TiVi system
Description: Device: TiVi system A galvanic current (0.1 mA) will be applied between 2 patches on the forearm of patient and protocol was repeated at 4 minutes.~Microvascular response to current application (CIV) will be recorded by TiVi system 10 minutes later.~Measurement of the value of skin blood flow (by TiVi system) at the stimulated area as compare to a non stimulated adjacent skin value taken as a reference Usual treatment will be recorded
Study: NCT00869882

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Circumferential arthrodesis
Description: Patients are carefully positioned in the proned position and submitted to a posterior surgical approach under general anaesthesia. Surgical levels are viewed laterally by mean of intraoperative radiographs which can be performed at surgeon's demand during the whole surgery time.~The preceding procedure is performed. In case of foraminal stenosis, decompression is performed at the same time as discal approach via the narrowest foramen.~In addition to this, before preparation of bed for bone grafting, nerve roots are retracted and the disc nucleus is removed entirely, then endplate decortication is performed. The disc space is distracted. The most anterior part of the disc space is packed with cancellous bone. A cage packed with bone is inserted into the anterior portion of the interspace. According to cage location, bone graft could be inserted in the posterior portion of the interspace. Cage placement is radiologically checked.~The end of the procedure is the same as for GPLI.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Posterolateral fusion with instrumentation
Description: Patients are carefully positioned in pronation and submitted to a posterior surgical approach under general anaesthesia. Surgical levels are viewed laterally by mean of intraoperative radiographs performed at surgeon's demand during the whole surgery time.~Pedicle screw instrumentation is performed, followed by posterior neural decompression depending on the type of stenosis:~* Central stenosis: decompression is performed including medial facectomy, laminectomy;~* Foraminal stenosis: foraminotomy is performed, while preserving a graft bed as large as possible;~* Pure foraminal stenosis: spinal duct is not opened. Local bone is harvested from the lamina and the spinous process and carefully fragmented for autologous graft.~Subperiosteal dissection is performed between the transverse processes and lateral aspects of the facet joints.~Two rods are placed and locked on screws in maximum compression to optimize segmental lordosis.~Bone autograft is placed into this bed.
Study: NCT02826369

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 3.0 Tesla in Magnetic Resonance Imaging
Description: Eligible patient will have a standard MRI. The images taken before 4min30 and after 6min after to the injection of gadolimium contrast medium will be carried out with the standard image acquisition.~The images taken between 4min30 and 6min after the injection of gadolimium contrast medium will be carried out with the compressed sensing image acquisition.
Study: NCT04145037

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AVR-RD-02
Description: AVR-RD-02 Drug product: active substance is autologous CD34+ enriched hematopoietic stem cells (HSCs) that have been genetically modified ex vivo with a lentiviral vector (LV) to contain a ribonucleic acid (RNA) transcript that, after reverse transcription, results in codon-optimized, complementary deoxyribonucleic acid (cDNA) that, upon its integration into human genome, encodes for functional human glucocerebrosidase (GCase).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AVR-RD-02
Description: AVR-RD-02 Drug product: active substance is autologous CD34+ enriched hematopoietic stem cells (HSCs) that have been genetically modified ex vivo with a lentiviral vector (LV) to contain a ribonucleic acid (RNA) transcript that, after reverse transcription, results in codon-optimized, complementary deoxyribonucleic acid (cDNA) that, upon its integration into human genome, encodes for functional human glucocerebrosidase (GCase).
Study: NCT03070509

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine
Description: lisdexamfetamine 50 mg single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine
Description: lisdexamfetamine 50 mg single dose
Study: NCT02772575

Intervention type: PROCEDURE
Intervention: Hepatic trans-arterial embolization (TAE)

Intervention type: DEVICE
Intervention: MRI/CT scan

Intervention type: PROCEDURE
Intervention: biopsy

Intervention type: OTHER
Intervention: blood draw
Study: NCT02909036

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Melphalan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegfilgrastim

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous Hematopoietic Progenitor Cell Transplant
Study: NCT01191060

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide, Bortezomib
Description: Lenalidomide/Bortézomib/Dexamethasone cycles:~Number of cycles: 8 cycles for arm A~Cycle length~Dosage:~* Lenalidomide: 25 mg/day on days 1-14 of each cycle~* Bortézomib: 1.3 mg/m2 on days 1, 4, 8, and 11 for 1 cycle of each cycle~Maintenance phase (12 months):~Cycle length: 28 days Dosage: Lenalidomide: 10 mg/day continuously for 28 days during 3 months and if the participant tolerates 10 mg/day without complication, a dose increase to 15 mg/day will be allowed

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide, Bortezomib
Description: Lenalidomide Bortezomib Dexamethasone cycles:~Number of cycles: 5 cycles for arm B~Cycle length~Dosage:~* Lenalidomide: 25 mg/day on days 1-14 of each cycle~* Bortézomib: 1.3 mg/m2 on days 1, 4, 8, and 11 for 1 cycle of each cycle~Maintenance phase (12 months):~Cycle length: 28 days Dosage: Lenalidomide: 10 mg/day continuously for 28 days during 3 months and if the participant tolerates 10 mg/day without complication, a dose increase to 15 mg/day will be allowed
Study: NCT00525265

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OPC-41061(Tolvaptan)
Description: Subjects will be orally administered OPC-41061 7.5 mg or 15 mg once daily after breakfast for seven days.
Study: NCT03196466

Intervention type: BIOLOGICAL
Intervention: lamotrigine
Description: titration

Intervention type: BIOLOGICAL
Intervention: topiramate
Description: titration

Intervention type: BIOLOGICAL
Intervention: topiramate
Description: titration

Intervention type: BIOLOGICAL
Intervention: oxcarbazepine
Description: titration

Intervention type: BIOLOGICAL
Intervention: oxcarbazepine
Description: titration

Intervention type: BIOLOGICAL
Intervention: stiripentol
Description: titration

Intervention type: BIOLOGICAL
Intervention: stiripentol
Description: titration

Intervention type: BIOLOGICAL
Intervention: clobazam
Description: titration
Study: NCT00525265

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will be orally administered placebo once daily after breakfast for seven days.
Study: NCT00073827

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: levalbuterol tartrate MDI
Description: levalbuterol 90 mcg QID

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: racemic albuterol MDI
Description: racemic albuterol 180 mcg QID

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo MDI QID
Study: NCT03555630

Intervention type: DIAGNOSTIC_TEST
Intervention: Thromboelastogram
Description: Blood sample processing for thromboelastogram

Intervention type: DIAGNOSTIC_TEST
Intervention: Thromboelastogram
Description: Blood sample processing for thromboelastogram
Study: NCT02206022

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil
Description: Pain's evaluation for Remifentanil Group

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: CVC pain's evaluation after local anesthesia + placebo infusion
Study: NCT03491423

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Short and fast step test without measurement of pulmonary gas exchange
Description: For one minute, the patient should climb up and down a 17.5 cm high step as quickly as possible while holding onto a bar in front of the step.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: glucose meter
Description: glucose meter to measure lactatemia

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ECG / heart rate
Description: ECG and heart rate (HR) collection by telemetry

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaires
Description: VAS pain assessment and evaluation of effort perception according to Borg's scale

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Short and fast step test with measurement of pulmonary gas exchange
Description: For one minute, the patient should climb up and down a 17.5 cm high step as quickly as possible while holding onto a bar in front of the step.